What it is
A dual GIP and GLP-1 receptor agonist that combines two gut-hormone pathways involved in appetite, insulin signaling, and fat metabolism.
Tirzepatide5 MGMetabolic collection
5 MG per vial · Box of 10
A dual GIP and GLP-1 receptor agonist studied for combined effects on appetite, insulin signaling, and fat metabolism.
Secure checkout is available through PeptidePay and NOWPayments.
Product guide
A dual GIP and GLP-1 receptor agonist that combines two gut-hormone pathways involved in appetite, insulin signaling, and fat metabolism.
In SURMOUNT-1, the highest studied dose group had an average 20.9% weight reduction at 72 weeks, compared with 3.1% in the placebo group.
Research-use noticeThis catalogue summary is educational, not medical advice or a recommendation for use. For qualified laboratory research only—not for human, clinical, veterinary, or household use.